Mandy Fluitt, APRN
Adult Health · Fort Smith, ARNPI 1386042927
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 256 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,658 and has fallen 97.8% since, to $37 in 2025. Among adult health clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$734
- Novo Nordisk$534
- AstraZeneca$465
- Lilly USA, LLC$348
- Abbott$236
- Insmed, Inc.$206
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 50 | $734 |
| Novo Nordisk | 26 | $534 |
| AstraZeneca(2 entities) | 15 | $465 |
| Lilly USA, LLC | 26 | $348 |
| Abbott | 12 | $236 |
| Insmed, Inc. | 9 | $206 |
| Pfizer | 12 | $187 |
| Bayer | 13 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $153 |
| Amgen(2 entities) | 9 | $135 |
| Biohaven Pharmaceuticals, Inc. | 12 | $113 |
| Amarin Pharma, Inc. | 8 | $111 |
| Boehringer Ingelheim | 5 | $91 |
| Johnson & Johnson | 7 | $90 |
| Viiv Healthcare Company | 5 | $86 |
| Astellas Pharma US Inc | 5 | $77 |
| Dexcom, Inc. | 5 | $72 |
| GSK | 5 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $64 |
| Currax Pharmaceuticals LLC | 4 | $57 |
| Exact Sciences | 3 | $43 |
| Novartis | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Dynavax Technologies Corporation | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Biogen | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,271 in reported general payments places this provider in the 90th percentile of 154 adult health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 110 | $114,634 |
| MounjaroTirzepatide | 17 | $31,779 |
| XareltoRivaroxaban | 33 | $31,575 |
| OtezlaApremilast | 12 | $28,944 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $27,811 |
| OzempicSemaglutide | 14 | $25,533 |
| JardianceEmpagliflozin | 29 | $24,602 |
| LinzessLinaclotide | 16 | $21,186 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,210 |
| FarxigaDapagliflozin Propanediol | 18 | $15,145 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $13,352 |
| Triamcinolone Acetonide | 56 | $7,049 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 174 | $4,571 |
| Potassium Chloride | 230 | $4,152 |
| Gabapentin | 173 | $3,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $187 | $114,634110 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $69 | $32,56250 claims |
| Lilly USA, LLCMounjaro | $348 | $31,77917 claims |
| Johnson & JohnsonXarelto | $90 | $31,57533 claims |
| AmgenOtezla | $135 | $28,94412 claims |
| Novo NordiskOzempic | $534 | $25,53314 claims |
| Boehringer IngelheimJardiance | $91 | $24,60229 claims |
| AbbVieLinzess, Synthroid | $734 | $23,86245 claims |
| AstraZenecaFarxiga | $465 | $15,14518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 154 adult health providers in Arkansas.
Other adult health in Fort Smith
- Gina NullFort Smith$8K
- Connie WardFort Smith$5K
- Chasidy McAllisterFort Smith$3K
- Courtney GueyeFort Smith$2K
- Elizabeth CharlesFort Smith$2K
- Ann HarpFort Smith$2K
- Melanie GramlingFort Smith$1K
- Paula BrosnanFort Smith$1K
- Holly MooreLittle Rock$59K
- Deborah ShipmanJonesboro$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.